Overview

This trial is active, not recruiting.

Conditions primary myelofibrosis, secondary myelofibrosis, myeloid malignancies
Treatment imetelstat
Phase phase 2
Sponsor Janssen Research & Development, LLC
Start date October 2012
End date May 2017
Trial size 81 participants
Trial identifier NCT01731951, CP14B019, CR107110

Summary

This pilot clinical trial studies how well imetelstat sodium works in treating patients with primary or secondary myelofibrosis and other myeloid malignancies. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Myelofibrosis (MF) participants will receive Imetelstat, 9.4 milligram per kilogram (mg/kg), intravenously [IV] as 2 hour infusion, on Day 1 of every 21-day cycle as long as they derive clinical benefit or until study end.
imetelstat GRN163L
Imetelstat Sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until study end. with the following dose and schedule: Starting doses are 7.5 mg/kg or 9.4 mg/kg from weekly to every four weeks based on indication as per arms.
(Experimental)
MF participants will receive Imetelstat, 9.4mg/kg, IV as 2 hour infusion, on Day 1, 8, 15 of Cycle 1, then Day 1 of each subsequent 21-day cycle as long as they derive clinical benefit or until study end.
imetelstat GRN163L
Imetelstat Sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until study end. with the following dose and schedule: Starting doses are 7.5 mg/kg or 9.4 mg/kg from weekly to every four weeks based on indication as per arms.
(Experimental)
Blast phase MF participants will receive Imetelstat, 9.4mg/kg, IV as 2 hour infusion, on Day 1, 8, 15, 22 of every 28-day cycle as long as they derive clinical benefit or until study end.
imetelstat GRN163L
Imetelstat Sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until study end. with the following dose and schedule: Starting doses are 7.5 mg/kg or 9.4 mg/kg from weekly to every four weeks based on indication as per arms.
(Experimental)
MF participants with spliceosome mutations or ring sideroblasts will receive Imetelstat, 7.5mg/kg, IV as 2 hour infusion, on Day 1 of every 28-day cycle as long as they derive clinical benefit or until study end.
imetelstat GRN163L
Imetelstat Sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until study end. with the following dose and schedule: Starting doses are 7.5 mg/kg or 9.4 mg/kg from weekly to every four weeks based on indication as per arms.
(Experimental)
MF participants without spliceosome mutations or ring sideroblasts will receive Imetelstat, 9.4mg/kg on Day1 of every 28-day cycle as long as they derive clinical benefit or until study end.
imetelstat GRN163L
Imetelstat Sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until study end. with the following dose and schedule: Starting doses are 7.5 mg/kg or 9.4 mg/kg from weekly to every four weeks based on indication as per arms.
(Experimental)
Myelodysplastic syndromes (MDS)/ myeloproliferative neoplasm (MPN) or MDS participants with spliceosome mutations or ring sideroblasts will receive Imetelstat, 7.5mg/kg on Day 1 of every 28-day cycle as long as they derive clinical benefit or until study end.
imetelstat GRN163L
Imetelstat Sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until study end. with the following dose and schedule: Starting doses are 7.5 mg/kg or 9.4 mg/kg from weekly to every four weeks based on indication as per arms.

Primary Outcomes

Measure
MF patients: Overall response rate defined as a clinical improvement (CI), partial remission (PR), or complete remission (CR) according to the IWG-MRT consensus criteria
time frame: Up to 3 years
MDS patients: Overall response rate according to the IWG response criteria in myelodysplasia
time frame: Up to 3 years

Secondary Outcomes

Measure
Maximum grade for each type of adverse event for each patient
time frame: Up to 5 years
Spleen response defined as either a minimum 50% reduction in palpable splenomegaly of a spleen that is at least 10 cm at baseline or a spleen that is palpable at more than 5 cm at baseline becomes not palpable
time frame: Up to 3 years
Proportion of patients achieving transfusion independence
time frame: Up to 3 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Diagnosis of one of the following: - primary myelofibrosis (PMF) per the revised World Health Organization (WHO) criteria - post-polycythemia vera/essential thrombocythemia myelofibrosis (Post-ET/PV MF) per the International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria - High-risk or Intermediate-2 risk MF (as defined by the Dynamic International Prognostic Scoring System [DIPSS-plus]) - Life expectancy of greater than or equal to (>=) 12 weeks - Able to provide informed consent and be willing to sign an informed consent form - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 - Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2.5 x upper limit of normal (ULN) (or =< 5 x ULN if in the investigator's opinion the elevation is due to extramedullary hematopoiesis) - Serum glutamic pyruvate transaminase (SGPT) alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) (or =<5 x ULN if in the investigator's opinion the elevation is due to extramedullary hematopoiesis) - Total bilirubin =< 3.0 mg/dL (or direct bilirubin < 1 mg/dL) - Creatinine =< 3.0 mg/dL - Absolute neutrophil count >= 1000/microliter (mcL) - Platelet count >= 50,000/mcL - Absence of active treatment with systemic anticoagulation and a baseline prothrombin time (PT) and activated partial thromboplastin time (aPTT) that does not exceed 1.5 x ULN - Females of childbearing potential must have a negative pregnancy test =< 7 days prior to registration, unless they are surgically sterile for at least 3 months (i.e., hysterectomy), OR postmenopausal for at least 12 months (follicle-stimulating hormone [FSH] >30 U/mL) - Females of childbearing potential must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through end of study; permitted methods for preventing pregnancy must be communicated to study subjects and their understanding confirmed - Males must agree to take appropriate precautions to avoid fathering a child (with at least 99% certainty) from screening through follow-up; permitted methods for preventing pregnancy should be communicated to the subjects and their understanding confirmed Exclusion Criteria: - Females who are pregnant or are currently breastfeeding - Any chemotherapy (e.g., hydroxyurea), immunomodulatory drug therapy (e.g., thalidomide), immunosuppressive therapy, corticosteroids > 10 mg/day prednisone or equivalent, growth factor treatment (e.g., erythropoietin) or Janus kinase (JAK) inhibitor therapy =< 14 days prior to registration - Subjects with another active malignancy - Note: patients with early stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin or cervical intraepithelial neoplasia are eligible for enrollment - Known positive status for human immunodeficiency virus (HIV) - Any unresolved toxicity greater or equal to grade 2 from previous anticancer therapy, except for stable chronic toxicities not expected to resolve - Incomplete recovery from any prior surgical procedures or had surgery =< 4 weeks prior to registration, excluding the placement of vascular access - Presence of acute active infection requiring antibiotics - Uncontrolled intercurrent illness or any concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol

Additional Information

Official title A Pilot Open-Label Study of the Efficacy and Safety of Imetelstat (GRN163L) in Myelofibrosis and Other Myeloid Malignancies
Description PRIMARY OBJECTIVES: I. To evaluate overall response rate. SECONDARY OBJECTIVES: I. To evaluate the safety and tolerability of imetelstat (imetelstat sodium) in myelofibrosis (MF). II. To evaluate the efficacy of imetelstat in the reduction of spleen size, as measured by physical examination (palpable distance from the left costal margin). III. To evaluate the efficacy of imetelstat in improving anemia or inducing red blood cell transfusion-independence in previously transfusion-dependent patients (per International Working Group for Myelofibrosis Research and Treatment [IWG-MRT] criteria). IV. To evaluate onset and durability of response as defined in primary and secondary endpoints EXPLORATORY OBJECTIVES: I. To evaluate the effect of imetelstat on bone marrow histology, karyotype and JAK2V617F allele burden II. To evaluate the effect of imetelstat on leukocytosis, circulating blast count, circulating immature myeloid cell count and thrombocytosis. OUTLINE: Patients receive imetelstat sodium intravenously (IV) over 2 hours on day 1. Patients may continue to receive imetelstat study treatment for as long as they derive clinical benefit or until study end. The study will end when all patients have discontinued study drug, the last patient enrolled has been treated for 5 years, or imetelstat is commercially available in the United States, whichever occurs first. After completion of study treatment, patients are followed up every 6 months for 5 years.
Trial information was received from ClinicalTrials.gov and was last updated in December 2016.
Information provided to ClinicalTrials.gov by Janssen Research & Development, LLC.